Ellen Zhuravsky, PA
Physician Assistant · Brooklyn, NYNPI 1356671671
Payments from drug & device makers
Across 269 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$679
- AstraZeneca$602
- Sumitomo Pharma America, Inc.$507
- Amgen$486
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$434
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,933100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,458 |
| GSK | 29 | $679 |
| AstraZeneca | 32 | $602 |
| Sumitomo Pharma America, Inc. | 18 | $507 |
| Amgen(2 entities) | 24 | $486 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $434 |
| Urovant Sciences Inc | 11 | $312 |
| Aimmune Therapeutics, Inc. | 7 | $196 |
| Novo Nordisk | 7 | $161 |
| Pfizer | 8 | $157 |
| Lilly USA, LLC | 7 | $156 |
| Biohaven Pharmaceuticals, Inc. | 7 | $139 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $93 |
| Boehringer Ingelheim | 3 | $80 |
| Nestle Healthcare Nutrition Inc. | 4 | $69 |
| Scilex Pharmaceuticals Inc. | 3 | $68 |
| Phathom Pharmaceuticals, Inc. | 2 | $64 |
| Shield Therapeutics Inc | 3 | $64 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Novartis | 2 | $50 |
| Bayer | 1 | $34 |
| Verona Pharma, Inc. | 1 | $26 |
| Exact Sciences | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $20 |
How this compares
$5,933 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 155 | $273,845 |
| CreonLipase/Protease/Amylase | 172 | $209,246 |
| Diclofenac Sodium | 436 | $196,909 |
| VascepaIcosapent Ethyl | 512 | $194,008 |
| LinzessLinaclotide | 356 | $193,637 |
| Nurtec OdtRimegepant Sulfate | 92 | $151,789 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 240 | $151,306 |
| GemtesaVibegron | 256 | $138,472 |
| JardianceEmpagliflozin | 169 | $116,222 |
| ProliaDenosumab | 61 | $100,558 |
| Dihydroergotamine Mesylate | 69 | $100,288 |
| EliquisApixaban | 134 | $97,772 |
| UbrelvyUbrogepant | 51 | $85,642 |
| MounjaroTirzepatide | 84 | $83,744 |
| Repatha SureclickEvolocumab | 122 | $80,117 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Ubrelvy, Restasis, Qulipta | $1,458 | $567,815696 claims |
| Aimmune Therapeutics, Inc.Zenpep | $196 | $273,845155 claims |
| PfizerNurtec Odt, Eliquis | $157 | $249,561226 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $679 | $163,885269 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $507 | $138,472256 claims |
| Boehringer IngelheimJardiance | $80 | $116,222169 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $602 | $109,423168 claims |
| Lilly USA, LLCMounjaro, Trulicity | $156 | $109,104111 claims |
| AmgenProlia | $486 | $100,55861 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $434 | $44,78983 claims |
| Novo NordiskOzempic | $161 | $44,13738 claims |
| NovartisEntresto | $50 | $13,74220 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.
Other physician assistant in Brooklyn
- Kaitlyn NelsonBrooklyn$289K
- Melissa VelezBrooklyn$68K
- Steven KongBrooklyn$66K
- Hong ChenBrooklyn$57K
- Lindsey AxtBrooklyn$52K
- Gregory CelestinBrooklyn$41K
- Henry YuBronx$1M
- Michael AsbachAmherst$962K
- Janelle BunceJamestown$565K
- Kristyl Cuenca-SiskoNew York$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.